Cargando…
Administration of amniotic fluid derived extracellular vesicle is associated with decreased crp in COVID-19 patients
Autores principales: | Mitrani, M., Bellio, M.A., Haskell, G., Shapiro, G.C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Society for Cell & Gene Therapy. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111902/ http://dx.doi.org/10.1016/S1465324921002887 |
Ejemplares similares
-
Treatment of a COVID-19 long hauler with an amniotic fluid-derived extracellular vesicle biologic
por: Mitrani, Maria Ines, et al.
Publicado: (2021) -
Human amniotic fluid derived extracellular vesicles attenuate T cell immune response
por: del Rivero, Tania, et al.
Publicado: (2022) -
Case Report: Administration of Amniotic Fluid-Derived Nanoparticles in Three Severely Ill COVID-19 Patients
por: Mitrani, Maria Ines, et al.
Publicado: (2021) -
Proof-of-concept trial of an amniotic fluid-derived extracellular vesicle biologic for treating high risk patients with mild-to-moderate acute COVID-19 infection
por: Bellio, Michael A., et al.
Publicado: (2021) -
Procoagulant Activity in Amniotic Fluid Is Associated with Fetal-Derived Extracellular Vesicles
por: Butov, Kirill R., et al.
Publicado: (2022)